公司代码：600129 公司简称：太极集团 重庆太极实业（集团）股份有限公司 2018 年第三季度报告 二○一八年十月 2018 年第三季度报告 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 1 / 21 | 目录 | | --- | | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 叶静涛 | 独立董事 | 因工作原因 | 刘云 | | 王启兵 | 董事 | 因工作原因 | 蒋茜 | 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 减(%) | | | --- | --- | --- ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 5,145,673,755.71, representing a 15.79% increase compared to CNY 4,444,112,317.17 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was CNY 54,307,355.52, a significant increase of 56.29% from CNY 34,747,895.77 in the previous year[22]. - The net cash flow from operating activities improved to CNY 9,096,536.55, a turnaround from a negative cash flow of CNY -75,264,348.66 in the same period last year, marking a 112.09% increase[22]. - The total assets at the end of the reporting period reached CNY 11,932,554,743.32, an increase of 11.91% from CNY 10,662,435,509.78 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company increased by 155.86% to CNY 3,141,470,638.85 from CNY 1,227,810,925.04 at the end of the previous year[22]. - Basic earnings per share for the first half of 2018 were CNY 0.0975, up 19.78% from CNY 0.0814 in the same period last year[23]. - The company achieved operating revenue of 5.146 billion RMB, an increase of 15.79% from 4.444 billion RMB in the same period last year[35]. - Net profit attributable to shareholders reached 54.31 million RMB, up 56.29% from 34.75 million RMB year-on-year[35]. Cash Flow and Financial Position - Operating cash flow improved significantly, with a net cash flow from operating activities of 9.10 million RMB, a turnaround from a negative cash flow in the previous year[40]. - Cash and cash equivalents increased to ¥1,869,675,986.92, accounting for 15.67% of total assets, up from 10.86% in the previous period[44]. - Long-term borrowings rose to ¥1,690,017,168.00, a 99.99% increase from ¥845,056,368.00 in the previous period, indicating a significant shift in the company's financing structure[44]. - The company's capital surplus increased dramatically by 850.25% to ¥2,047,916,957.20, compared to ¥215,513,945.96 in the previous period[44]. - Total liabilities decreased to ¥8,793,207,270.51 from ¥9,445,082,266.57, a reduction of about 6.9%[118]. - Total assets increased to ¥11,932,554,743.32 from ¥10,662,435,509.78, showing a growth of approximately 11.9%[118]. - The company's equity attributable to shareholders rose to ¥3,141,470,638.85 from ¥1,227,810,925.04, an increase of about 156.5%[118]. Market and Operational Developments - Key products with significant sales growth include: Yibaoshiling with 670 million RMB (up 136%), Lofenitine sustained-release tablets with 154 million RMB (up 57%), and Tianmasu injection with 131 million RMB (up 252%)[36]. - The company’s industrial sales revenue increased by 35.17% due to optimized agency cooperation and active terminal expansion[36]. - The commercial distribution system expanded, with hospital deliveries becoming a new growth point in key areas of Sichuan and Chongqing[37]. - The company is conducting consistency evaluations for 48 chemical drug products, with one already completing bioequivalence studies[37]. - Research and development expenses increased to 26.97 million RMB, reflecting a commitment to enhancing product development[41]. - The company’s sales expenses rose by 81.56% to 1.334 billion RMB, driven by increased market development efforts[40]. Risk Management and Compliance - There were no significant risks that materially affected the company's production and operations during the reporting period[9]. - The pharmaceutical industry faces significant risks due to policy changes, including GMP and GSP certifications, which can impact revenue and profit margins[52]. - The company has not faced any penalties or corrective actions involving its directors, supervisors, or senior management[59]. - The company has not reported any overdue guarantees, indicating a stable financial position[71]. - The company has not disclosed any major related party transactions that have progressed or changed since the last announcement[61]. Environmental and Social Responsibility - The company has not experienced any environmental accidents or violations, and pollution control facilities are operating normally[85]. - The wastewater treatment plant at the Nanchong factory has a daily processing capacity of 1,000 tons, meeting the third-level discharge standard[84]. - The company actively integrates into the national poverty alleviation strategy, implementing the "8+1" poverty alleviation project[79]. - The company established a poverty alleviation fund and developed order-based planting bases for traditional Chinese medicine in impoverished areas[74]. - A total of 1,943 registered poor individuals were helped to escape poverty during the reporting period[77]. Shareholder and Corporate Governance - The total number of shares increased from 426,894,000 to 556,890,744 after the issuance[95]. - The top ten shareholders held a total of 184,886,858 shares, representing 33.20% of the total shares[102]. - Taiji Group Limited increased its holdings by 12,999,674 shares during the reporting period[102]. - The company has seen significant turnover in its board and management, with multiple directors and executives resigning and new appointments made, indicating a potential shift in strategic direction[109][110]. - The company appointed a new chairman, Bai Lixi, and a new general manager, Yuan Yonghong, as part of its leadership restructuring[111]. Accounting Policies and Financial Reporting - The financial statements comply with the requirements of the enterprise accounting standards, accurately reflecting the company's financial position and operating results[153]. - The company applies the equity method for joint ventures and recognizes its share of assets, liabilities, and income accordingly[161]. - The company has established specific accounting policies and estimates tailored to its operational characteristics, ensuring accurate financial reporting[152]. - The company recognizes impairment losses for non-current assets held for sale, which are first deducted from goodwill and then proportionally from the carrying amounts of other non-current assets[181].

Financial Performance - In 2017, the company's operating revenue reached ¥8,734,522,957.80, an increase of 9.84% compared to ¥7,951,835,647.34 in 2016[22] - The net profit attributable to shareholders for 2017 was ¥98,133,504.24, a significant decrease of 88.54% from ¥856,210,859.09 in 2016[22] - The total distributable profit for investors was ¥460,012,654.95, with no cash dividends or stock bonuses declared for the year due to high capital demands from expansion[6] - The company's net profit attributable to shareholders decreased to CNY 1,227,810,925.04, a decline of 3.89% compared to CNY 1,284,509,575.76 in 2016[23] - Basic earnings per share dropped significantly to CNY 0.23, down 88.56% from CNY 2.01 in 2016[24] - The total assets increased by 11.91% to CNY 10,662,435,509.78 from CNY 9,527,777,979.41 in 2016[23] - The weighted average return on equity fell to 7.74%, a decrease of 68.49 percentage points from 76.23% in 2016[24] - The company reported a significant increase in non-operating income, including government subsidies amounting to CNY 47,995,293.40[28] - The company achieved a net profit attributable to shareholders of 853,318,457.42 RMB for the year 2016, with a cash dividend distribution of 3 RMB per 10 shares[116] Operational Highlights - The company is focusing on expanding its production capacity and building new facilities to meet increasing sales demands[6] - The company completed a major asset restructuring in 2016, which significantly impacted the profit sources in 2017, shifting from restructuring gains to operational profits[24] - The company has over 1,500 drug approvals, including 55 exclusive production varieties and more than 50 national protected traditional Chinese medicine varieties[35] - The company operates 12 pharmaceutical factories and over 30 pharmaceutical commercial companies, making it one of the largest pharmaceutical groups in China with a complete industry chain[39] - The company’s subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, is the largest production base for oral liquids and syrups in Asia, with an annual output of 2 billion oral liquids and 100 million syrups[39] - The company has developed advanced technologies in sustained-release and rapid-release formulations, positioning itself as a leader in the domestic market[39] - The company has established a marketing network with over 10,000 Tongjun Pavilion pharmacies across the country[43] - The company has a strong marketing network across the country, with a focus on self-operated sales and academic marketing strategies[38] Research and Development - The company has developed a strong R&D system, successfully developing over 40 new drugs and obtaining more than 30 national new drug certificates[47] - The company’s R&D expenditure increased by 27.42% to 67.69 million yuan, reflecting a commitment to innovation and product development[55] - The company is focusing on the development of new products and technologies, particularly in traditional Chinese medicine and chemical preparations[75][76] - The company is focusing on the development of modern traditional Chinese medicine and natural plant drugs, particularly in cardiovascular, diabetes, digestive, and respiratory systems[83] - The company has ongoing projects such as the "Huo Xiang Zheng Qi Oral Liquid" with a cumulative R&D investment of 2,476.34 million RMB[87] - The "Qi Deng Ming Mu Capsule" is currently in Phase II clinical trials, with a total R&D investment of 1,830.53 million RMB[87] - The company plans to initiate important R&D projects in the upcoming year, including the "Qi Deng Ming Mu Capsule" and "Dan Qi Tong Mai Pian" in clinical trials[90] Market Strategy - The company aims to become the largest plant medicine manufacturer globally and the most extensive retail pharmacy enterprise within ten years, targeting to rank among the top five in China's pharmaceutical industry by 2021[107] - In 2018, the company plans to achieve over 18% growth in industrial sales and over 16% growth in commercial sales, focusing on high-margin products and reducing costs[109][111] - The company expects sales of its core product, Huoxiang Zhengqi Oral Liquid, to exceed 1.6 billion yuan in 2018, with additional products like Yibaoshiling projected to surpass 1 billion yuan[110] - The company is committed to enhancing its marketing strategies, including academic marketing, to boost sales of effective traditional Chinese medicine products[110][111] - The company plans to accelerate the development and market launch of new products, including Qideng Mingmu Capsules, while also focusing on the consistency evaluation of generic drugs[109] Financial Management - The company successfully raised approximately 1.997 billion yuan through a private placement, enhancing its asset structure and improving financial indicators[47] - The company has increased its long-term borrowings, which were reclassified as current liabilities, indicating a shift in financial strategy[70] - The company reported a significant increase in income tax expenses, rising by 232.64% to 86,497,583.78 CNY[64] - The company’s financial expenses decreased slightly by 1.15% to 225,204,342.98 CNY[64] - The company has maintained a strong financial position with no contingent liabilities reported[136] Environmental and Social Responsibility - The company invested RMB 304.45 million in poverty alleviation efforts, establishing 43,000 mu of traditional Chinese medicine planting bases in nine impoverished counties[144] - The company helped 383 registered impoverished individuals increase their income through its poverty alleviation initiatives[144] - The company’s subsidiary, Fuling Pharmaceutical Factory, was listed as a key wastewater monitoring enterprise by the Chongqing Environmental Protection Bureau for 2017[150] - Fuling Pharmaceutical has maintained stable pollutant emissions, complying with environmental standards without any violations or accidents reported in 2017[155] - The company has established emergency response plans for environmental incidents, with completed risk assessments and registrations[152] Corporate Governance - The company held 4 shareholder meetings during the reporting period, ensuring equal voting rights for all shareholders[184] - The company’s board of directors convened 6 meetings, ensuring compliance with relevant laws and regulations[186] - The company has established a communication mechanism with its controlling shareholder to ensure timely information disclosure[185] - The company emphasizes the importance of investor relations management, ensuring fair and timely information disclosure to investors[187] - The company has no major litigation or arbitration matters in the current year[124]

2018 年第一季度报告 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 12,056,514,882.62 | 10,662,435,509.78 | | 13.07 | | 归属于上市公司 | 3,171,034,859.91 | 1,227,810,925.04 | | 158.27 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的 | 11,837,713.35 | -91,634,772.92 | | 2,971.18 | | 现金流量净额 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减（%） | | | 营业收入 | 2,249,899,093.13 | 1,868,253,622.58 | | 20.43 | | 归属于上市公司 | 11,634,688.35 | 2,313,506.07 | | 40 ...

2017 年第三季度报告 公司代码：600129 公司简称：太极集团 重庆太极实业（集团）股份有限公司 2017 年第三季度报告 二 0 一七年十月 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 8 | 2017 年第三季度报告 一、 重要提示 2017 年第三季度报告 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人白礼西、主管会计工作负责人袁永红 及会计机构负责人（会计主管人员） 周万森保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | --- | --- | --- | --- | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2017 was ¥4,444,112,317.17, representing a 14.34% increase compared to ¥3,886,622,674.49 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥34,747,895.77, a significant decrease of 96.40% from ¥964,429,836.12 in the previous year[18]. - The basic earnings per share for the first half of 2017 was ¥0.0814, down 96.40% from ¥2.2592 in the same period last year[19]. - The weighted average return on net assets decreased by 69.91 percentage points to 2.71% from 72.62% in the previous year[19]. - The net cash flow from operating activities was -¥75,264,348.66, an improvement of 59.96% compared to -¥187,977,591.44 in the same period last year[18]. - The total assets at the end of the reporting period were ¥9,395,131,765.65, a slight decrease of 0.27% from ¥9,420,217,211.21 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were ¥1,275,296,712.69, down 0.72% from ¥1,284,509,575.76 at the end of the previous year[18]. - The company reported a net profit of ¥5,487.69 million for the period, with total assets of ¥285,555.55 million[44]. - The company reported a significant drop in investment income, with a loss of CNY 1,824,784.81 compared to a gain of CNY 1,140,585,532.30 in the previous year[91]. - The company reported a total comprehensive income of -185,525,161.76 RMB for the first half of 2017, compared to 751,713,494.89 RMB in the same period last year, highlighting a significant downturn[95]. Revenue and Sales - The sales revenue of the core product, Huoxiang Zhengqi Oral Liquid, reached CNY 557 million, a growth of 45% year-on-year[30]. - The company reported a 22.11% increase in industrial product sales revenue compared to the previous year[30]. - The company’s commercial sales revenue grew by 9.48% year-on-year, indicating successful market expansion strategies[31]. - Total revenue from sales of goods and services reached 4,479,041,718.79 RMB, up from 4,167,461,256.65 RMB year-over-year, showing a growth of approximately 7.5%[98]. Costs and Expenses - The company’s operating costs increased by 9.21% to CNY 3.01 billion, attributed to higher sales volume[33]. - Total operating costs for the first half of 2017 were CNY 4,361,039,171.92, up from CNY 4,041,951,896.33, reflecting a year-over-year increase of 7.9%[91]. - The company incurred total operating expenses of 5,163,382,737.34 RMB, compared to 4,982,616,058.65 RMB in the previous year, reflecting a rise in operational costs[98]. Investments and Financing - The company plans to implement a non-public stock issuance following approval from the China Securities Regulatory Commission[31]. - The company raised 442,600,000.00 RMB through borrowings, indicating a reliance on debt financing[102]. - The company provided non-operating fund occupation of 193 million yuan from its subsidiaries to related parties, which constitutes a significant financial issue[49]. - The company received a disciplinary criticism from the Shanghai Stock Exchange for non-compliance with regulations regarding related party transactions[50]. Assets and Liabilities - Total current assets decreased from CNY 4,917,915,535.68 to CNY 4,828,208,543.80, a decline of approximately 1.8%[83]. - Total liabilities decreased slightly from CNY 8,144,214,077.87 to CNY 8,115,267,762.30, a reduction of about 0.4%[86]. - The company's equity attributable to shareholders decreased from CNY 1,284,509,575.76 to CNY 1,275,296,712.69, a reduction of approximately 0.9%[86]. - The company’s total liabilities and equity at the end of the period amounted to CNY 1,651,115,169.85[108]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 49,751[72]. - The largest shareholder, Taiji Group Co., Ltd., held 165,690,203 shares, representing 38.81% of the total shares[75]. - The second-largest shareholder, Chongqing Fuling Xilan Biotechnology Co., Ltd., held 11,895,294 shares, accounting for 2.79%[75]. - The company reported no changes in its share capital structure during the reporting period[71]. Compliance and Governance - The company has committed to strict compliance with the Company Law and the Shanghai Stock Exchange listing rules to ensure accurate information disclosure[51]. - The company has not reported any significant changes in its stock incentive plans or employee stock ownership plans[52]. - The company has no major litigation or arbitration matters during the reporting period[50]. - The company has not made any changes to significant accounting policies or estimates during the reporting period[178]. Research and Development - Research and development expenses increased by 17.02% to CNY 26.03 million, reflecting the company's commitment to enhancing R&D efforts[34]. - The company is investing in the establishment of new medical and pharmaceutical entities, including Hainan Taiji Medical Health Co., Ltd. and Chongqing Tongjun Pavilion Fengdu Pharmaceutical Distribution Co., Ltd.[54]. Risk Factors - There were no significant risks that materially affected the company's operations during the reporting period[6]. - The company faces significant risks due to policy impacts in the pharmaceutical industry, including new GMP and GSP certifications and the potential for substantial changes in net profit compared to the previous year[42]. Cash Flow - The net cash flow from operating activities was -75,264,348.66 RMB, an improvement from -187,977,591.44 RMB in the same period last year, indicating better cash management[98]. - Cash and cash equivalents at the end of the period stood at 588,732,606.94 RMB, down from 629,688,204.53 RMB at the end of the previous period[99]. - The company reported a net cash flow from investment activities of -55,662,577.14 RMB, compared to 236,204,659.04 RMB in the previous period, indicating a significant decrease[102]. Community and Social Responsibility - The company has established a poverty alleviation fund to support targeted poverty alleviation efforts in underdeveloped areas[66]. - The company is actively implementing industrial poverty alleviation through the development of traditional Chinese medicine production[66]. - The company is developing a traditional Chinese medicine planting base in nine poverty-stricken counties, covering an area of 58,000 acres to help local farmers increase income[67].